Cell Biosciences Launches First Platform Commercially | GenomeWeb

Cell Biosciences this week made its first official commercial launch with the CB1000 protein analysis system.

The system measures post-translational medications such as phosphorylation using capillary-based nanofluidic immunoassays. Built on technology developed for its earlier instrument, the Firefly 3000, the new system uses a capillary that is filled with a sample filled with separation buffer and standards. Proteins are then separated by isoelectric points based on isoelectric focusing.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Familial DNA searches in criminal cases are winning over some critics, the Los Angeles Times reports.

In Nucleic Acids Research this week: ProTraits includes genetic, phenotypic data on bacteria, archaea; Candida albicans assembly 22; and more.

The Wall Street Journal reports that researchers are looking beyond Cas9 for CRISPR editing.

In PNAS this week: miR-515 levels higher in women with preeclampsia, horizontal gene transfer in parasitic plants, and more.